<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7281404\results\search\drug\results.xml">
  <result pre="trials to be justified for clinical use. COVID-19 SARS-CoV-2 remdesivir" exact="chloroquine" post="lopinavir favipiravir baricitinib interferons ACE2 TMPRSS2 1. Introduction The"/>
  <result pre="to be justified for clinical use. COVID-19 SARS-CoV-2 remdesivir chloroquine" exact="lopinavir" post="favipiravir baricitinib interferons ACE2 TMPRSS2 1. Introduction The pandemic"/>
  <result pre="is under review [14]. 3.1.1. Remdesivir (GS-5734) Remdesivir is an" exact="adenosine" post="analog that leads to the premature or delayed termination"/>
  <result pre="currently investigating the drug; see Table 1. 3.1.2. Lopinavir and" exact="Ritonavir" post="The combination of lopinavir and ritonavir was developed as"/>
  <result pre="see Table 1. 3.1.2. Lopinavir and Ritonavir The combination of" exact="lopinavir" post="and ritonavir was developed as protease inhibitors for the"/>
  <result pre="1. 3.1.2. Lopinavir and Ritonavir The combination of lopinavir and" exact="ritonavir" post="was developed as protease inhibitors for the treatment of"/>
  <result pre="the liver by microsomal enzymes â€œcytochrome 3A4 (CYP3A4)â€� and â€œCYP3A5.â€�" exact="Ritonavir" post="inhibits the CYP3A4 enzyme and results in increased concentrations"/>
  <result pre="inhibits the CYP3A4 enzyme and results in increased concentrations of" exact="lopinavir" post="when the two drugs are co-administered [24]. Lopinavir/ritonavir combination"/>
  <result pre="improvement, viral load, or mortality [26]. However, the combination of" exact="lopinavir" post="and ritonavir was included in two arms of the"/>
  <result pre="load, or mortality [26]. However, the combination of lopinavir and" exact="ritonavir" post="was included in two arms of the SOLIDARITY trial"/>
  <result pre="another smaller study (150 participants were recruited) in comparison to" exact="hydroxychloroquine" post="and a control (no intervention group) for 7â€&quot;10 days"/>
  <result pre="days (NCT04307693); see Table 1. Interestingly, a computational study suggested" exact="lopinavir" post="(as well as oseltamivir) as a potential therapy for"/>
  <result pre="as a potential therapy for COVID-19 [27]. 3.1.3. Darunavir and" exact="Cobicistat" post="Another combination of protease inhibitors was previously reported to"/>
  <result pre="volunteers, with the advantage of avoiding the adverse effects of" exact="ritonavir" post="[28]. Cobicistat is an analog of ritonavir and a"/>
  <result pre="the advantage of avoiding the adverse effects of ritonavir [28]." exact="Cobicistat" post="is an analog of ritonavir and a potent CYP3A"/>
  <result pre="adverse effects of ritonavir [28]. Cobicistat is an analog of" exact="ritonavir" post="and a potent CYP3A inhibitor. It has no antiviral"/>
  <result pre="no antiviral activity. Like ritonavir, it inhibits CYP2D6 and p-glycoprotein." exact="Cobicistat" post="also inhibits drug transporters, e.g., organic anion transport protein"/>
  <result pre="trials were registered to compare the combination of darunavir and" exact="cobicistat" post="for conventional treatment in patients with COVID-19 (NCT04252274 and"/>
  <result pre="with other antiviral drugs (including lopinavir/ritonavir); see Table 1. 3.1.5." exact="Ribavirin" post="The drug is an inosine monophosphate dehydrogenase inhibitor. The"/>
  <result pre="acute respiratory distress syndrome (ARDS) in patients with SARS-CoV [33]." exact="Ribavirin" post="was also used in combination with lopinavir/ritonavir and an"/>
  <result pre="after starting the combination therapy in severe cases [36]. Interestingly," exact="ribavirin" post="inhibited SARS-COV-2 replication at low concentrations in Caco-2 cells"/>
  <result pre="results of this study are concordant with previous reports of" exact="ribavirin" post="effectiveness against other coronaviruses including HCoV-43, CoV-NL63, and MERS-CoV-16,"/>
  <result pre="other coronaviruses including HCoV-43, CoV-NL63, and MERS-CoV-16, but not SARS-CoV-126." exact="Ribavirin" post="is under investigation in COVID-19 in combination with interferon-Î±"/>
  <result pre="and inflammasome, thus inducing cell pyroptosis in SARS-CoV-2 infection [46]." exact="Tranilast" post="is an antagonist of NLRP3 that inhibits the inflammasome"/>
  <result pre="is an antagonist of NLRP3 that inhibits the inflammasome pathway." exact="Tranilast" post="is a tryptophan analog used to treat allergic conditions,"/>
  <result pre="MERS-CoV. IFNÎ²1 up-regulates CD73 in the pulmonary endothelium, leading to" exact="adenosine" post="secretion. Adenosine is an anti-inflammatory molecule that supports the"/>
  <result pre="up-regulates CD73 in the pulmonary endothelium, leading to adenosine secretion." exact="Adenosine" post="is an anti-inflammatory molecule that supports the endothelial barrier."/>
  <result pre="(five million U twice a day), combined with the antiviral" exact="ribavirin" post="[62]. Clinical trials have been recently registered to assess"/>
  <result pre="lopinavir/ritonavir and IFNÎ±2b (ChiCTR2000029387) or a combination of lopinavir/ritonavir with" exact="ribavirin" post="and subcutaneously-administered IFNÃŸ1b (NCT04276688) for the treatment of COVID-19;"/>
  <result pre="more than placebo in patients treated with baricitinib [74]. 4.2." exact="Ruxolitinib" post="Ruxolitinib is an orally available and potent JAK1 and"/>
  <result pre="than placebo in patients treated with baricitinib [74]. 4.2. Ruxolitinib" exact="Ruxolitinib" post="is an orally available and potent JAK1 and JAK2"/>
  <result pre="the FDA in November 2011 [75]. The pharmacokinetic analysis of" exact="ruxolitinib" post="predicted that the unbound plasma concentration required to inhibit"/>
  <result pre="reduce the inflammatory response of the host by inhibiting JAK." exact="Ruxolitinib" post="is currently being studied to combine it with COVID-19"/>
  <result pre="who acquired these infections were taking concomitant immunosuppressants, such as" exact="methotrexate" post="or corticosteroids, and, as such, the drug should be"/>
  <result pre="severe COVID-19. Patients with diabetes may get macular edema upon" exact="fingolimod" post="treatment [100]. A clinical trial has been registered to"/>
  <result pre="treatment [100]. A clinical trial has been registered to use" exact="fingolimod" post="at a dose of 0.5 mg daily for three"/>
  <result pre="(NCT04280588). 5. Other Anti-Infective Agents Repurposed to Treat COVID-19 5.1." exact="Chloroquine" post="and Hydroxychloroquine Both chloroquine (CQ) and hydroxychloroquine (HCQ) are"/>
  <result pre="Other Anti-Infective Agents Repurposed to Treat COVID-19 5.1. Chloroquine and" exact="Hydroxychloroquine" post="Both chloroquine (CQ) and hydroxychloroquine (HCQ) are antimalarial drugs"/>
  <result pre="Agents Repurposed to Treat COVID-19 5.1. Chloroquine and Hydroxychloroquine Both" exact="chloroquine" post="(CQ) and hydroxychloroquine (HCQ) are antimalarial drugs that are"/>
  <result pre="Treat COVID-19 5.1. Chloroquine and Hydroxychloroquine Both chloroquine (CQ) and" exact="hydroxychloroquine" post="(HCQ) are antimalarial drugs that are also prescribed in"/>
  <result pre="in treating autoimmune diseases [101]. According to the literature, both" exact="chloroquine" post="and hydroxychloroquine possess antiviral activity against several viruses. CQ,"/>
  <result pre="autoimmune diseases [101]. According to the literature, both chloroquine and" exact="hydroxychloroquine" post="possess antiviral activity against several viruses. CQ, through the"/>
  <result pre="the SARS-CoV-2 spike protein [108]. To date, clinical studies investigating" exact="hydroxychloroquine" post="or chloroquine have been limited, and their role in"/>
  <result pre="spike protein [108]. To date, clinical studies investigating hydroxychloroquine or" exact="chloroquine" post="have been limited, and their role in COVID-19 treatment"/>
  <result pre="versus 12.5%, respectively) [111]. In this study, the use of" exact="azithromycin" post="in combination with HCQ was apparently associated with a"/>
  <result pre="study were a concern, and the biologic basis for using" exact="azithromycin" post="in this setting is unclear. Another small observational study"/>
  <result pre="the activity of the non-structural enzyme 3 helicase [113]. Moreover," exact="ivermectin" post="inhibits dengue viruses and interrupts virus replication [114]. Ivermectin"/>
  <result pre="which mediates the nuclear transport of several RNA viruses. Thus," exact="ivermectin" post="blocks the nuclear trafficking of RNA viral proteins. Ivermectin"/>
  <result pre="polymerase in dengue viruses [115,116]. To investigate the effect of" exact="ivermectin" post="on SARS-CoV-2, Vero/hSLAM cells with SARS-CoV-2 that were isolated"/>
  <result pre="cells with SARS-CoV-2 that were isolated Australia/VIC01/2020 were treated with" exact="ivermectin" post="[117]. Ivermectin administration resulted in a successful viral loss"/>
  <result pre="in viral RNA at 72 h. The authors hypothesized that" exact="ivermectin" post="exerts its antiviral activity by inhibiting the nuclear import"/>
  <result pre="importinÎ±/Î²1â€&quot;the same mechanism discussed before for other RNA viruses. 5.3." exact="Azithromycin" post="Macrolides are a unique class of antibiotics that include"/>
  <result pre="effects. Lately, the anti-viral effects of macrolides have been investigated." exact="Erythromycin" post="is the first macrolide proved to have efficacy in"/>
  <result pre="of rhinovirus and influenza virus [118]. On the other hand," exact="clarithromycin" post="and azithromycin have shown higher effectivity towards rhinovirus, respiratory"/>
  <result pre="and influenza virus [118]. On the other hand, clarithromycin and" exact="azithromycin" post="have shown higher effectivity towards rhinovirus, respiratory syncytial virus,"/>
  <result pre="and Ebola viruses have been shown to be inhibited by" exact="azithromycin" post="[120,121]. During the early phase of influenza virus infection,"/>
  <result pre="azithromycin [120,121]. During the early phase of influenza virus infection," exact="azithromycin" post="has been found to block influenza virus endocytosis into"/>
  <result pre="might be an effective treatment for COVID-19. The mechanism of" exact="azithromycin" post="against SARS-CoV-2 is unclear; however, it may be similar"/>
  <result pre="[111]. Several pathways for the suspected antiviral effects found with" exact="azithromycin" post="have been suggested. Firstly, as mentioned regarding CQ and"/>
  <result pre="have been suggested. Firstly, as mentioned regarding CQ and HCQ," exact="azithromycin" post="is a weak base that could inhibit endocytosis, thus"/>
  <result pre="inhibit endocytosis, thus limiting viral entry and replication [122]. Secondly," exact="azithromycin" post="directly affects the activity of bronchial epithelial cells and"/>
  <result pre="improving lung function [123]. Thirdly, there is evidence suggesting that" exact="azithromycin" post="increases the production of IFN via the stimulation of"/>
  <result pre="to a reduction of viral replication [124]. Lastly and recently," exact="azithromycin" post="was shown to directly intervene with the SARS-CoV-2 host"/>
  <result pre="viral spread and pathogenesis in an infected host [16,138], and" exact="camostat" post="mesylate is a serine protease inhibitor that inhibits SARS-CoV"/>
  <result pre="of both influenza and parainfluenza viruses. In experimentally infected mice," exact="camostat" post="was also found to prevent the development of pneumonia"/>
  <result pre="prevent the development of pneumonia and viral myocarditis [140]. Moreover," exact="camostat" post="mesylate has been found to help to slow down"/>
  <result pre="the treatment of chronic pancreatitis patients in Japan [141]. Therefore," exact="camostat" post="mesylate could also be of benefit in patients infected"/>
  <result pre="model of MERS-CoV infectionProc. Natl. Acad. Sci. USA20201176771677610.1073/pnas.192208311732054787 20.WangM.CaoR.ZhangL.YangX.LiuJ.XuM.ShiZ.HuZ.ZhongW.XiaoG.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="studies of drug repurposing and synergism of lopinavir, oseltamivir and" exact="ritonavir" post="binding with SARS-CoV-2 Protease against COVID-19J. Biomol. Struct. Dyn.20201710.1080/07391102.2020.1752802"/>
  <result pre="81.FangW.YangY.MaY.HongS.LinL.HeX.XiongJ.LiP.ZhaoH.HuangY.et al.Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus" exact="cisplatin" post="for nasopharyngeal carcinoma: Results from two single-arm, phase 1"/>
  <result pre="in multiple sclerosisAnn. Neurol.20116975977710.1002/ana.2242621520239 100.CoppesO.J.M.GutierrezI.RederA.T.KsiazekS.BernardJ.Severe early bilateral macular edema following" exact="fingolimod" post="therapyMult. Scler. Relat. Disord.2013225625810.1016/j.msard.2012.11.00425877733 101.LeeS.J.SilvermanE.BargmanJ.M.The role of antimalarial agents"/>
  <result pre="IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modesRheumatology20064570371010.1093/rheumatology/kei28216418198 107.SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of" exact="chloroquine" post="on viral infections: An old drug against todayâ€™s diseases?Lancet"/>
  <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome Coronavirus"/>
  <result pre="Dis. Off. Publ. Infect. Dis. Soc. Am.202010.1093/cid/ciaa237 109.JieZ.HeH.XiH.ZhiZ.Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumoniaChin. J."/>
  <result pre="COVID-192020Available online: https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19(accessed on 20 April 2020) 111.GautretP.LagierJ.-C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: Results of an open-label"/>
  <result pre="rapid antiviral clearance or clinical benefit with the combination of" exact="hydroxychloroquine" post="and azithromycin in patients with severe COVID-19 infectionMed. Mal."/>
  <result pre="clearance or clinical benefit with the combination of hydroxychloroquine and" exact="azithromycin" post="in patients with severe COVID-19 infectionMed. Mal. Infect.202010.1016/j.medmal.2020.03.00632240719 113.BurgR.W.MillerB.M.BakerE.E.BirnbaumJ.CurrieS.A.HartmanR.KongY.L.MonaghanR.L.OlsonG.PutterI.et"/>
  <result pre="replication of HIV-1 and dengue virusBiochem. J.201244385185610.1042/BJ2012015022417684 117.CalyL.DruceJ.D.CattonM.G.JansD.A.WagstaffK.M.The FDA-approved drug" exact="ivermectin" post="inhibits the replication of SARS-CoV-2 in vitroAntivir. Res.202017810478710.1016/j.antiviral.2020.10478732251768 118.MinJ.Y.JangY.J.Macrolide"/>
  <result pre="impair phagocytosis in J774 macrophagesExp. Cell Res.20022818610010.1006/excr.2002.561312441132 123.CramerC.L.PattersonA.AlchakakiA.SoubaniA.O.Immunomodulatory indications of" exact="azithromycin" post="in respiratory disease: A concise review for the clinicianPostgrad."/>
  <result pre="and III interferon responsesAntimicrob. Agents Chemother.20196310.1128/AAC.00394-19 125.SandeepS.McGregorK.Energetics based modeling of" exact="hydroxychloroquine" post="and azithromycin binding to the SARS-CoV-2 spike (S)proteinâ€&quot;ACE2 ComplexChemRxiv202010.26434/chemrxiv.12015792.v2"/>
  <result pre="interferon responsesAntimicrob. Agents Chemother.20196310.1128/AAC.00394-19 125.SandeepS.McGregorK.Energetics based modeling of hydroxychloroquine and" exact="azithromycin" post="binding to the SARS-CoV-2 spike (S)proteinâ€&quot;ACE2 ComplexChemRxiv202010.26434/chemrxiv.12015792.v2 126.KubaK.ImaiY.Ohto-NakanishiT.PenningerJ.M.Trilogy of"/>
  <result pre="influenzaAntivir. Res.201192273610.1016/j.antiviral.2011.07.01421802447 141.JiaD.TaguchiM.OtsukiM.Preventive and therapeutic effects of the protease inhibitor" exact="camostat" post="on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient ratsPancreas200530546115632700"/>
  <result pre="ACE 2 (rhACE2). Potential pharmacotherapeutic approaches include the use of" exact="camostat" post="mesylate (which is a TMPRSS2 inhibitor) to block the"/>
  <result pre="elevated ALT/AST. Known hypersensitivity CYP2C8 and aldehyde oxidase inhibitor https://clinicaltrials.gov/ct2/show/NCT04376814" exact="Ribavirin" post="Inhibits viral RdRp Oral Flu-like symptoms, depression, suicide, insomnia,"/>
  <result pre="depression or suicidal ideation, and liver failure. Inhibits metabolism of" exact="zidovudine" post="https://clinicaltrials.gov/ct2/show/NCT04350684(IFNÎ²-1)https://clinicaltrials.gov/ct2/show/NCT04276688(IFNÎ²-1)https://clinicaltrials.gov/ct2/show/NCT04350671(IFNÎ²-1)https://clinicaltrials.gov/ct2/show/NCT04343976(IFN-Î») Immuno-Modulatory Agents Baricitinib JAK-1 and JAK-2 inhibitor Oral"/>
  <result pre="(minor), OAT1/3, and P-glycoprotein/ABCB1. Potentially significant interactions may exist https://clinicaltrials.gov/ct2/show/NCT04358614https://clinicaltrials.gov/ct2/show/NCT04340232https://clinicaltrials.gov/ct2/show/NCT04346147https://clinicaltrials.gov/ct2/show/NCT04320277https://clinicaltrials.gov/ct2/show/NCT04373044https://clinicaltrials.gov/ct2/show/NCT04321993https://clinicaltrials.gov/ct2/show/NCT04345289" exact="Ruxolitinib" post="JAK1 and JAK2 inhibitor Oral Uncontrolled HIV infection, active"/>
  <result pre="who developed these infections were taking concomitant immunosuppressants, such as" exact="methotrexate" post="or corticosteroids. Known or expected to have allergic reactions"/>
  <result pre="â‰¥ 500 msec, heart block, CAD, pregnancy, and known hypersensitivity" exact="Ketoconazole" post="increases the drug level; vaccination may be less effective"/>
  <result pre="less effective https://clinicaltrials.gov/ct2/show/NCT04280588 Other Anti-Infective Agents Repurposed to Treat COVID-19" exact="Chloroquine" post="and hydroxychloroquine Inhibits viral entry and endocytosis Oral QTc"/>
  <result pre="https://clinicaltrials.gov/ct2/show/NCT04280588 Other Anti-Infective Agents Repurposed to Treat COVID-19 Chloroquine and" exact="hydroxychloroquine" post="Inhibits viral entry and endocytosis Oral QTc prolongation, hypoglycemia,"/>
  <result pre="myalgia, blurred vision, and Mazzotti reaction (with onchocerciasis) Hypersensitivity to" exact="ivermectin" post="Warfarin https://clinicaltrials.gov/ct2/show/NCT04360356https://clinicaltrials.gov/ct2/show/NCT04351347https://clinicaltrials.gov/ct2/show/NCT04374019 Azithromycin Inhibits viral entry and endocytosis Oral"/>
  <result pre="blurred vision, and Mazzotti reaction (with onchocerciasis) Hypersensitivity to ivermectin" exact="Warfarin" post="https://clinicaltrials.gov/ct2/show/NCT04360356https://clinicaltrials.gov/ct2/show/NCT04351347https://clinicaltrials.gov/ct2/show/NCT04374019 Azithromycin Inhibits viral entry and endocytosis Oral QTc"/>
  <result pre="and Mazzotti reaction (with onchocerciasis) Hypersensitivity to ivermectin Warfarin https://clinicaltrials.gov/ct2/show/NCT04360356https://clinicaltrials.gov/ct2/show/NCT04351347https://clinicaltrials.gov/ct2/show/NCT04374019" exact="Azithromycin" post="Inhibits viral entry and endocytosis Oral QTc prolongation, diarrhea,"/>
  <result pre="angioedema and hereditary or idiopathic angioedemaCoadministration of neprilysin inhibitors with" exact="aliskiren" post="in patients with diabetes mellitus or with renal impairment"/>
  <result pre="Member/ Multidrug Resistance Protein; ACEi: angiotensin converting enzyme inhibitor; ALT:" exact="alanine" post="transaminase; AST: aspartate transaminase; AV: atrio-ventricular; BCRP/ABCG2: Breast cancer"/>
 </snippets>
</snippetsTree>
